Skip to main content
IMS Events Main banner

  1. Home

  • Wednesday, Sep 17th
    16:40 - 16:50 East Coast USA Time
    (OA-49) Insights from Cytogenetic Subgroup Analyses in the GMMG-CONCEPT trial with Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma
    Location: Room 718
    Abstract Presenter: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Thursday, Sep 18th
    12:20 - 12:26 East Coast USA Time
    (PA-379) Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone
    Location: Room 714A
    Abstract Presenter: Robert Z. Orlowski, MD, PhD (he/him/his) – Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Thursday, Sep 18th
    15:24 - 15:32 East Coast USA Time
    (OA-63) Efficacy and Safety of Iberdomide, Daratumumab, and Dexamethasone, in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients: Initial Analysis of the GEM-IBERDARAX trial
    Location: Hall FG
    Abstract Presenter: Verónica González-Calle, MD, PhD (she/her/hers) – Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC)
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Thursday, Sep 18th
    15:32 - 15:40 East Coast USA Time
    (OA-70) Patient-Reported Outcomes (PROs) and Safety in Patients (Pts) With NDMM Achieving MRD Negativity and ≥CR (MRDneg) in the Phase 3 PERSEUS and CEPHEUS Trials
    Location: Hall FG
    Abstract Presenter: Jesus San Miguel, PhD. MD. (he/him/his) – Cancer Center Clínica Universidad de Navarra
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Friday, Sep 19th
    12:47 - 12:53 East Coast USA Time
    (PA-416) Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 Study
    Location: Room 714A
    Abstract Presenter: Karthik Ramasamy, MBBS FRCP FRCPath PhD – University of Oxford and Oxford University Hospitals NHS FT
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Friday, Sep 19th
    14:47 - 15:05 East Coast USA Time
    (OA-61) A Randomized Phase 2 Study of Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Transplant-Ineligible/Deferred Patients with Newly Diagnosed Multiple Myeloma: Alliance Foundation Trial 41
    Location: Hall FG
    Abstract Presenter: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Saturday, Sep 20th
    08:00 - 08:10 East Coast USA Time
    (OA-50) Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from the CC-220-MM-001 Trial
    Location: Room 701
    Abstract Presenter: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Saturday, Sep 20th
    08:10 - 08:20 East Coast USA Time
    (OA-46) Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022-05)
    Location: Room 701
    Abstract Presenter: Arthur F. Bobin (he/him/his) – University Hospital of Poitiers
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Saturday, Sep 20th
    08:20 - 08:30 East Coast USA Time
    (OA-48) Final Analysis of the GEM-BELA-VRd Phase II Trial: Belantamab Mafodotin Plus VRd in Newly Diagnosed Transplant-Eligible Myeloma After 2 Years of Maintenance with Belantamab and Lenalidomide
    Location: Room 701
    Abstract Presenter: Verónica González-Calle, MD, PhD (she/her/hers) – Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC)
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Saturday, Sep 20th
    08:30 - 08:40 East Coast USA Time
    (OA-47) Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study
    Location: Room 701
    Abstract Presenter: Larry D. Anderson, Jr., MD, PhD (he/him/his) – Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
  • Saturday, Sep 20th
    08:40 - 08:50 East Coast USA Time
    (OA-51) Carfilzomib, Lenalidomide, and Dexamethasone (KRd) after Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Analysis of High-Risk Subset in Phase 3 ATLAS Trial
    Location: Room 701
    Abstract Presenter: Andrzej Jakubowiak, MD, PhD – The University of Chicago
    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)